Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 20, 2021 09:00 ET | Source: Zylö Therapeutics

Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials

Funds to be used for scale-up, implementation of cGMP quality system, and pre-IND FDA meeting GREENVILLE, SC, July 20, 2021 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the...
April 01, 2019 11:43 ET | Source: Taconic Biosciences

Taconic Biosciences Licenses the Wild Mouse Gut Microbiome from the National Institute of Diabetes and Digestive and Kidney Diseases

RENSSELAER, N.Y., April 01, 2019 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces it has obtained a license to the Wild...
July 13, 2017 13:00 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808

SAN DIEGO, July 13, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that...
April 14, 2015 14:00 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance Stable, Non-Aqueous Glucagon for Treatment of Congenital Hyperinsulinism, an Orphan Disease

Austin, Texas, April 14, 2015 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), an Austin-based, emerging biopharmaceutical company developing patient-friendly injectable treatments for...
February 11, 2013 09:42 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Closed 2012 with $6M In Additional Funding

Austin, TX, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, emerging pharmaceutical company developing patient-friendly injectable treatments for diabetes,...
July 31, 2012 10:41 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance Stable, Non-Aqueous Glucagon for Bi-Hormonal Artificial Pancreas

Austin, TX, July 31, 2012 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, emerging biopharmaceutical company developing patient-friendly injectable treatments for diabetes...